Applied Therapeutics 

$0.103000
83
+$0.00+0.19% Monday 21:00
+$0.00+2.04%Tuesday 00:41Pre-market

Statistics

Day High
0.11
Day Low
0.1005
52W High
1.5
52W Low
0.09
Volume
2,690,459
Avg. Volume
16,032,278
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13MarExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-0.67
-0.49
-0.3
-0.12
Expected EPS
-0.116667
Actual EPS
N/A

Financials

-23,214.07%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
910,000Revenue
-211.25MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including genetic disorders, which overlaps with Applied Therapeutics' focus on rare diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals competes in the space of rare diseases with its RNAi therapeutics, directly competing with Applied Therapeutics' approach to targeting rare metabolic diseases.
Biogen
BIIB
Mkt Cap32.28B
Biogen is involved in the discovery and development of therapies for serious diseases including rare genetic disorders, making it a competitor in the biopharmaceutical space targeting similar patient populations.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical specializes in enzyme replacement therapies and other drug development for rare genetic diseases, directly competing with Applied Therapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its work in biotechnology and developing treatments for a variety of diseases, including rare diseases, making it a competitor in the biopharmaceutical field.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for serious illnesses that may overlap with Applied Therapeutics' target areas, making it a competitor.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a research-based biopharmaceutical company that develops drugs for serious diseases, including areas that may compete with Applied Therapeutics' focus on rare diseases.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a global healthcare company with a focus on diabetes care and other serious chronic conditions, potentially competing in the metabolic disease space with Applied Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company with a broad portfolio that includes treatments for rare diseases and other serious conditions, making it a competitor across various therapeutic areas.

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Show more...
CEO
Mr. John H. Johnson
Employees
35
Country
United States
ISIN
US03828A1016

Listings

0 Comments

Share your thoughts

FAQ

What is Applied Therapeutics stock price today?
The current price of APLT is $0.10 USD — it has increased by +0.19% in the past 24 hours. Watch Applied Therapeutics stock price performance more closely on the chart.
What is Applied Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Applied Therapeutics stocks are traded under the ticker APLT.
Is Applied Therapeutics stock price growing?
APLT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Applied Therapeutics has showed a -77.86% decrease.
What is Applied Therapeutics revenue for the last year?
Applied Therapeutics revenue for the last year amounts to 910,000 USD.
What is Applied Therapeutics net income for the last year?
APLT net income for the last year is -211.25M USD.
How many employees does Applied Therapeutics have?
As of September 04, 2026, the company has 35 employees.
In which sector is Applied Therapeutics located?
Applied Therapeutics operates in the Health & Wellness sector.
When did Applied Therapeutics complete a stock split?
Applied Therapeutics has not had any recent stock splits.
Where is Applied Therapeutics headquartered?
Applied Therapeutics is headquartered in New York, United States.